Mylan
OGIVRI
Manufacturer:
Mylan
Name:
OGIVRI
HCPCS Code Descriptor:
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
Category:
Q Code
HCPCS:
Q5114
NDC(s):
67457-0991-15, 67457-0847-44
Primary Type:
Oncology Biosimilar
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
OGIVRI is an Oncology Biosimilar drug manufactured by Mylan and administered via the Intravenous route of administration. The Q Code: Q5114 is aligned to the drug OGIVRI.
Ogivri (trastuzumab) is a cancer drug that targets the HER2 protein in cancer cells. This medication can be used to treat specific types of breast and stomach cancers. Ogivri can be used in combination with other cancer medications. Ogivri is manufactured by Mylan instituitional and is biosimilar to the medication Herceptin (J9356). Ogivri has been aligned to the HCPCS code Q5114 since July 2019. Patient assistance programs for this medication can be found through Viatris Patient Assistance.
Access Pricing and More By Registering
HCPCS Added Date:
7/1/19
HCPCS Effective Date:
7/1/19
HCPCS Short Description:
Inj ogivri 10 mg
Billing and Coding Guide:
https://www.viatrisadvocate.com/-/media/viatrisadvocatecom/pdf/ogiviri/tra-2019-0102-v2-coding-and-billing-guide-for-ogivri.pdf?la=en
Patient Assistance:
https://www.viatris.com/en-us/lm/united-states/patient-assistance-program